CHANGE FROM ANALYSIS PLANNED IN PROTOCOL The following changes in the methodologies specified in the protocol were made. Analysis Populations A mITT population was defined, and will include all enrolled patients who had a mea surable disease at baseline, received at least 1 dose of study drug and had at least one post- baseline tumor assessment ≥8 weeks from first drug administration confirmed by the modified RANO criteria A Per Protocol population was defined, and will include all mITT patients wh o completed the initial dosing (12 doses for Stage 1 subjects and 16 doses for Stage 2 subjects). Effi cacy data for the PP population will also be analyzed to evaluate the importance of initial dosing. Efficacy Endpoint ORR was no longer to be a primary endpoint. Instead, it is considered to be a seconda ry efficacy variable. Duration of disease control (DDC) was added as a secondary efficacy variable. Efficacy analyses using RECIST criteria were removed from the analysis plan. Certain sensitivity analysis will be performed using the RECIST response criteria . DocuSign Envelope ID: B3F56764-C440-4885-BA44-7578C4A73DB3 Stemline Therapeutics, Inc. Protocol: STML- 701-0114 Version 3.0, 10-JUL-2015 (Amendment 2) Statistical Analysis Plan Page 44 of 63 12.